Article

Interview with Dr Peter A Kaufman

Dr Peter A Kaufman, discussed the promising activity demonstrated by motesanib in a small phase 1b trial of women with locally recurrent, unresectable, or metastatic breast cancer.

Dr Peter A Kaufman, Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire, discussed the promising activity demonstrated by motesanib in a small phase 1b trial of women with locally recurrent, unresectable, or metastatic breast cancer.

MP3 DOWNLOAD: PETER_KAUFMAN.mp3

(Right click to download podcast)

Related Videos
Brigit Vogel, MD: Exploring Geographical Disparities in PAD Care Across US| Image Credit: LinkedIn
Eric Lawitz, MD | Credit: UT Health San Antonio
| Image Credit: X
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Ahmad Masri, MD, MS | Credit: Oregon Health and Science University
Stephen Nicholls, MBBS, PhD | Credit: Monash University
Marianna Fontana, MD, PhD: Nex-Z Shows Promise in ATTR-CM Phase 1 Trial | Image Credit: Radcliffe Cardiology
Zerlasiran Achieves Durable Lp(a) Reductions at 60 Weeks, with Stephen J. Nicholls, MD, PhD | Image Credit: Monash University
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
A. Sidney Barritt, MD | Credit: UNC School of Medicine
© 2024 MJH Life Sciences

All rights reserved.